江苏澳洋健康产业股份有限公司 关于全资子公司增资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告的 虚假记载、误导性陈述或者重大遗漏负连带责任。 一、增资事项概述 二、增资对象的基本情况 关于全资子公司增资的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-24 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）于 2025 年 8 月 4 日召开第九届董事会第五次会议，审议通过了《关于全资子公司 增资的议案》。公司全资子公司张家港澳洋医院有限公司（以下简称"澳洋医院"）， 拟以自有资金向其全资子公司张家港澳洋护理院有限公司（以下简称"澳洋护理 院"）增资，增资金额为人民币 1,700 万元。本次增资完成后，澳洋护理院的注 册资本由人民币 500 万元变更为人民币 2,200 万元。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次增资 事项属于公司董事会审议权限范围内，无需提交股东大会。本次增资事项不属于 关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 11、最近一年及一期主要财务数据 1、公司名称：张家港澳洋护理院 ...

江苏澳洋健康产业股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 第九届董事会第五次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-25 董事会 二〇二五年八月五日 - 1 - 表决结果：同意9票，反对0票，弃权0票。 上述议案的详细内容，请见同日《证券时报》或公司指定信息披露网站（巨 潮资讯网 www.cninfo.com.cn）。 江苏澳洋健康产业股份有限公司 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第五次会议于 2025 年 7 月 24 日以通讯方式发出会议通知，于 2025 年 8 月 4 日下午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名，实 际出席会议董事 9 名。会议由公司董事长沈学如先生主持，符合《公司法》及公 司《章程》的有关规定。公司监事及高管列席了会议。会议经认真审议，通过如 下议案： 一、审议通过《关于全资子公司增资的议案》 公司全资子公司张家港澳洋医院有限公司，拟以自有资金向其全资子公司张 家港澳洋 ...

关于控股股东股权结构变动的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-23 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 特别提示: 公司控股股东澳洋集团有限公司(以下简称"澳洋集团")本次股权结构变动， 未导致其所持有的公司股份数量及持股比例发生变化，未导致本公司的控股股东 及实际控制人发生变化。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）近日接到 控股股东澳洋集团有限公司（以下简称"澳洋集团"）的通知，获悉澳洋集团因减 资导致股权结构发生变动，现已办理完毕工商变更登记手续。现将有关情况公告 如下： 一、控股股东股权结构变动的基本情况 | 序号 | 股东名称 | 变动前 | | 变动后 | | | --- | --- | --- | --- | --- | --- | | | | 出资额（万元） | 占比（%） | 出资额（万元） | 占比（%） | | 1 | 沈学如 | 32,875.04 | 54.79 | 32,875.04 | 65.75 | | 2 | 朱宝元 | 11,924.96 | ...

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]

Group 1 - The high-pressure oxygen chamber concept increased by 2.63%, ranking 10th among concept sectors, with five stocks rising, including a 20% limit-up for Tiedao Heavy Industry [1] - Notable gainers in the high-pressure oxygen chamber sector include Innovation Medical and Samsung Medical, which rose by 3.29% and 0.96% respectively [1] - The sector experienced a net inflow of 170 million yuan from main funds, with Tiedao Heavy Industry receiving the highest net inflow of 120 million yuan [2] Group 2 - The top stocks by net inflow ratio in the high-pressure oxygen chamber sector are Tiedao Heavy Industry at 39.19%, International Medical at 4.88%, and Samsung Medical at 4.16% [3] - The trading volume and turnover rates for key stocks in the sector indicate significant investor interest, with Tiedao Heavy Industry showing a turnover rate of 0.97% [3] - Decliners in the sector included Dahu Co., which fell by 0.55%, and Aoyang Health, which decreased by 0.50% [4]

Group 1 - The high-pressure oxygen chamber concept increased by 3.78%, ranking 8th among concept sectors, with 8 stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading stocks in the high-pressure oxygen chamber sector included Weiao Co., International Medicine, and Dahu Co., which rose by 3.80%, 3.24%, and 2.44% respectively [1] - The high-pressure oxygen chamber sector saw a net inflow of 152 million yuan from main funds, with 6 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top net inflow stock was Tiebian Heavy Industry, with a net inflow of 60.89 million yuan, followed by International Medicine, Samsung Medical, and Aoyang Health with net inflows of 57.53 million yuan, 42.20 million yuan, and 22.89 million yuan respectively [2] - In terms of net inflow ratios, Aoyang Health, Tiebian Heavy Industry, and International Medicine had the highest ratios at 15.77%, 14.47%, and 11.68% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed significant activity, with Tiebian Heavy Industry achieving a daily increase of 19.90% and a turnover rate of 1.60% [3]

Core Viewpoint - The hair medical concept sector has shown a positive performance with a 1.77% increase, ranking 7th among various concept sectors, driven by significant gains in stocks like Xiaofang Pharmaceutical, Baicheng Pharmaceutical, and Jiuzhitang [1] Group 1: Sector Performance - The hair medical concept sector experienced a 1.77% increase, with 17 stocks rising, including Xiaofang Pharmaceutical (up 6.65%), Baicheng Pharmaceutical (up 6.05%), and Jiuzhitang (up 6.00%) [1] - The sector attracted a net inflow of 114 million yuan from main funds, with Jiuzhitang leading the inflow at 74.56 million yuan [1] Group 2: Fund Inflow Ratios - Baicheng Pharmaceutical, Aoyang Health, and Yisheng Pharmaceutical had the highest net inflow ratios at 10.73%, 7.21%, and 6.37% respectively [2] - Jiuzhitang recorded a net inflow of 74.56 million yuan with a turnover rate of 27.18% [2] - Other notable stocks include Langzi Co. (up 5.16% with a net inflow of 20.14 million yuan) and Aoyang Health (up 1.03% with a net inflow of 10.81 million yuan) [2]

Core Viewpoint - The company, Aoyang Health, is experiencing a decline in revenue and net profit, with a significantly high PE ratio compared to the industry average, indicating potential overvaluation in the current market context [1][2]. Group 1: Company Performance - On July 8, Aoyang Health's stock closed at 3.93 yuan, up 1.03%, with a rolling PE ratio of 106.26 times and a total market capitalization of 3.009 billion yuan [1]. - For Q1 2025, the company reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% [2]. - The company's sales gross margin stands at 15.09% [2]. Group 2: Industry Comparison - The average PE ratio for the healthcare services industry is 42.77 times, with a median of 47.19 times, positioning Aoyang Health at 41st in the industry ranking [1]. - The company’s PE (TTM) is significantly higher than the industry average, indicating a potential overvaluation [2]. - Other companies in the industry, such as WuXi AppTec and Kanglong Chemical, have much lower PE ratios, suggesting that Aoyang Health may be less attractive to investors based on valuation metrics [2]. Group 3: Company Operations and Achievements - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]. - The company has received several honors, including awards for quality management in hospitals and recognition as one of the top 100 non-public hospitals in China [1]. - Aoyang Hospital has signed an agreement with the China Trauma Rescue Alliance to enhance its emergency response capabilities, aiming to reduce mortality and disability rates among severely injured patients [1].

Market Performance - The hair medical concept sector rose by 2.34%, ranking 10th among concept sectors, with 19 stocks increasing in value, including JiuZhiTang which hit the daily limit, and TianEnKang, KangHui Pharmaceutical, and KangYuan Pharmaceutical which rose by 6.42%, 5.16%, and 4.55% respectively [1] - The top gainers in today's market include the fruit index at 4.73%, PCB concept at 3.27%, and AI mobile at 2.92%, while the military restructuring concept saw a decline of 1.49% [1] Capital Flow - The hair medical concept sector experienced a net inflow of 219 million yuan, with 11 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan. JiuZhiTang led with a net inflow of 172 million yuan, followed by ShuiYang Co., KangYuan Pharmaceutical, and NengTe Technology with net inflows of 34.25 million yuan, 21.05 million yuan, and 13.44 million yuan respectively [1] - In terms of capital inflow ratios, JiuZhiTang, ShuiYang Co., and KangHui Pharmaceutical had the highest net inflow rates at 33.17%, 6.81%, and 6.15% respectively [2] Stock Performance - JiuZhiTang saw a significant increase of 10.06% with a turnover rate of 7.62%, while ShuiYang Co. and KangYuan Pharmaceutical increased by 3.12% and 4.55% respectively [2] - Stocks such as *ST JinBi and AoYang Health experienced declines of 0.69% and 0.26% respectively, indicating some volatility within the sector [1][3]

Core Viewpoint - The company, Aoyang Health, has reported a significant decline in revenue and net profit for Q1 2025, while maintaining a high price-to-earnings (PE) ratio compared to the industry average, indicating potential overvaluation in the context of its financial performance [1][2]. Company Summary - Aoyang Health's closing stock price on July 1 was 3.96 yuan, reflecting a 1.54% increase, with a rolling PE ratio of 107.07 times and a total market capitalization of 3.032 billion yuan [1]. - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with its main products being medical services and pharmaceutical logistics [1]. - As of Q1 2025, two institutions held shares in Aoyang Health, with a total of 23,688.59 million shares valued at 791 million yuan [1]. Financial Performance - For Q1 2025, Aoyang Health reported an operating revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% compared to the previous year [2]. - The company's gross profit margin stood at 15.09% [2]. Industry Comparison - The average PE ratio for the medical services industry is 42.17 times, with a median of 44.15 times, positioning Aoyang Health at the 41st rank within the industry [1][2]. - Aoyang Health's PE (TTM) is significantly higher than the industry average, indicating a potential overvaluation relative to its peers [2].